Kansas-Missouri’s $34 million will translate biologic discoveries into U.S. production, while Virginia’s $16 million will develop and scale pharmaceutical manufacturing.
The collaboration has produced 20 AAV8 manufacturing batches, including 18 under cGMP conditions, supporting pivotal clinical development and future commercial-scale production.